Idexx Laboratories Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.74%.
Did IDXX Beat Earnings? Q1 2025 Results
IDEXX Laboratories posted a solid beat on both lines in Q1 2025, with earnings per share of $2.96 clearing the $2.84 consensus by 4.06% and revenue of $998.43 million edging past estimates by 0.20% on 3.6% year-over-year growth, as the veterinary diagnostics leader leaned on robust VetLab consumables demand to drive results. The standout driver was double-digit organic revenue growth in IDEXX VetLab consumables, fueled by a 9% expansion in the global premium instrument installed base, while gross margin widened 90 basis points to 62.4% on favorable product mix. A $0.08 per-share benefit from the resolution of a patent royalty dispute, which allowed IDEXX to reduce an $89 million accrual by roughly $9 million, also contributed to the EPS outcome. Looking ahead, management raised full-year 2025 revenue guidance to $4.10 billion–$4.21 billion and lifted EPS guidance to $11.93–$12.43, with the increases reflecting favorable foreign exchange tailwinds and the litigation adjustment, even as the company acknowledged estimated tariff headwinds from U.S. and Chinese trade measures embedded in its outlook.
- Double-digit IDEXX VetLab consumables organic revenue growth
- 9% year-over-year growth in global premium instrument installed base
- Sustained high customer retention and net price gains
- Net new customer gains and increased diagnostic utilization
- Gross margin expansion of 90 basis points to 62.4%
- Strong cloud-based software placement momentum
“IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dxâ„¢, in our North American reference laboratories.”
IDEXX Laboratories CEO, on the earnings call
Forward Guidance & Outlook
IDEXX raised its full-year 2025 revenue guidance to $4,095M–$4,210M (up $40M at midpoint), reflecting favorable FX from a weaker U.S. dollar, while maintaining organic revenue growth of 6%–9%. Reported revenue growth is now projected at 5%–8%. CAG Diagnostics recurring revenue growth guidance is 4%–7% reported and 5%–8% organic. Full-year EPS guidance was raised to $11.93–$12.43 (up $0.19), reflecting $0.11 from FX benefits and $0.08 from the litigation accrual adjustment, with reported EPS growth of 12%–17% and comparable growth of 8%–12%. Operating margin is projected at 31.1%–31.6% with comparable margin expansion of 30–80 basis points. Capital expenditures are expected at approximately $160M. Free cash flow conversion is projected at 80%–85% of net income. The guidance incorporates estimated tariff impacts on internationally sourced materials, including U.S. tariffs and China's retaliatory tariffs.
IDXX YoY Financials
IDXX Revenue by Segment
IDXX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.